Log in

NYSE:EWEdwards Lifesciences Competitors & Alternatives

$69.19
+0.19 (+0.28 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$68.80
Now: $69.19
$70.23
50-Day Range
$67.13
MA: $109.53
$224.72
52-Week Range
$51.51
Now: $69.19
$82.55
Volume2.05 million shs
Average Volume3.23 million shs
Market Capitalization$42.87 billion
P/E Ratio39.69
Dividend YieldN/A
Beta0.86

Competitors

Edwards Lifesciences (NYSE:EW) Vs. ABT, MDT, SYK, ISRG, BDX, and BSX

Should you be buying EW stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to Edwards Lifesciences, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), and Boston Scientific (BSX).

Edwards Lifesciences (NYSE:EW) and Abbott Laboratories (NYSE:ABT) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, profitability, institutional ownership, dividends and risk.

Insider and Institutional Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 73.6% of Abbott Laboratories shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500.

Profitability

This table compares Edwards Lifesciences and Abbott Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences24.71%31.83%20.29%
Abbott Laboratories11.15%18.61%8.61%

Valuation & Earnings

This table compares Edwards Lifesciences and Abbott Laboratories' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20
Abbott Laboratories$31.90 billion5.11$3.69 billion$3.2428.47

Abbott Laboratories has higher revenue and earnings than Edwards Lifesciences. Abbott Laboratories is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Edwards Lifesciences and Abbott Laboratories, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences171502.61
Abbott Laboratories241302.58

Edwards Lifesciences presently has a consensus price target of $82.7727, indicating a potential upside of 19.63%. Abbott Laboratories has a consensus price target of $100.2667, indicating a potential upside of 8.71%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts clearly believe Edwards Lifesciences is more favorable than Abbott Laboratories.

Summary

Edwards Lifesciences beats Abbott Laboratories on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Medtronic (NYSE:MDT) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, earnings, profitability, valuation, risk, institutional ownership and dividends.

Risk & Volatility

Edwards Lifesciences has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Medtronic has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.

Earnings and Valuation

This table compares Edwards Lifesciences and Medtronic's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20
Medtronic$28.91 billion4.32$4.79 billion$4.5920.30

Medtronic has higher revenue and earnings than Edwards Lifesciences. Medtronic is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and target prices for Edwards Lifesciences and Medtronic, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences171502.61
Medtronic162212.77

Edwards Lifesciences presently has a consensus price target of $82.7727, indicating a potential upside of 19.63%. Medtronic has a consensus price target of $114.5333, indicating a potential upside of 22.94%. Given Medtronic's stronger consensus rating and higher probable upside, analysts clearly believe Medtronic is more favorable than Edwards Lifesciences.

Insider & Institutional Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 81.1% of Medtronic shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by company insiders. Comparatively, 0.3% of Medtronic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Medtronic's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences24.71%31.83%20.29%
Medtronic16.56%12.17%6.79%

Summary

Medtronic beats Edwards Lifesciences on 8 of the 15 factors compared between the two stocks.

Stryker (NYSE:SYK) and Edwards Lifesciences (NYSE:EW) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.

Risk & Volatility

Stryker has a beta of 0.84, suggesting that its share price is 16% less volatile than the S&P 500. Comparatively, Edwards Lifesciences has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500.

Valuation & Earnings

This table compares Stryker and Edwards Lifesciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Stryker$14.88 billion4.63$2.08 billion$8.2622.27
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20

Stryker has higher revenue and earnings than Edwards Lifesciences. Stryker is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and Edwards Lifesciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Stryker14.47%24.90%11.10%
Edwards Lifesciences24.71%31.83%20.29%

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Stryker and Edwards Lifesciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Stryker271712.63
Edwards Lifesciences171502.61

Stryker currently has a consensus target price of $215.20, suggesting a potential upside of 16.99%. Edwards Lifesciences has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Given Edwards Lifesciences' higher possible upside, analysts clearly believe Edwards Lifesciences is more favorable than Stryker.

Insider & Institutional Ownership

71.3% of Stryker shares are held by institutional investors. Comparatively, 80.7% of Edwards Lifesciences shares are held by institutional investors. 6.8% of Stryker shares are held by company insiders. Comparatively, 1.5% of Edwards Lifesciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Edwards Lifesciences beats Stryker on 8 of the 15 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Intuitive Surgical (NASDAQ:ISRG) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Intuitive Surgical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences171502.61
Intuitive Surgical461202.36

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Intuitive Surgical has a consensus target price of $571.1176, suggesting a potential downside of 1.61%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Intuitive Surgical.

Earnings and Valuation

This table compares Edwards Lifesciences and Intuitive Surgical's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20
Intuitive Surgical$4.48 billion15.12$1.38 billion$9.9558.34

Intuitive Surgical has higher revenue and earnings than Edwards Lifesciences. Edwards Lifesciences is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Intuitive Surgical has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

80.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 87.3% of Intuitive Surgical shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 1.6% of Intuitive Surgical shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Intuitive Surgical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences24.71%31.83%20.29%
Intuitive Surgical30.11%17.40%14.87%

Summary

Intuitive Surgical beats Edwards Lifesciences on 9 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Becton Dickinson and (NYSE:BDX) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Edwards Lifesciences and Becton Dickinson and, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences171502.61
Becton Dickinson and08702.47

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Becton Dickinson and has a consensus target price of $273.80, suggesting a potential upside of 11.74%. Given Edwards Lifesciences' stronger consensus rating and higher probable upside, analysts plainly believe Edwards Lifesciences is more favorable than Becton Dickinson and.

Earnings and Valuation

This table compares Edwards Lifesciences and Becton Dickinson and's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20
Becton Dickinson and$17.29 billion3.84$1.23 billion$11.6820.98

Becton Dickinson and has higher revenue and earnings than Edwards Lifesciences. Becton Dickinson and is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500. Comparatively, Becton Dickinson and has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Institutional & Insider Ownership

80.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 85.8% of Becton Dickinson and shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by insiders. Comparatively, 0.1% of Becton Dickinson and shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Edwards Lifesciences and Becton Dickinson and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences24.71%31.83%20.29%
Becton Dickinson and6.10%15.75%6.37%

Summary

Edwards Lifesciences beats Becton Dickinson and on 8 of the 14 factors compared between the two stocks.

Edwards Lifesciences (NYSE:EW) and Boston Scientific (NYSE:BSX) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability.

Profitability

This table compares Edwards Lifesciences and Boston Scientific's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Edwards Lifesciences24.71%31.83%20.29%
Boston Scientific39.75%18.24%7.64%

Institutional and Insider Ownership

80.7% of Edwards Lifesciences shares are held by institutional investors. Comparatively, 90.1% of Boston Scientific shares are held by institutional investors. 1.5% of Edwards Lifesciences shares are held by insiders. Comparatively, 0.7% of Boston Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Edwards Lifesciences has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500. Comparatively, Boston Scientific has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and Boston Scientific's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Edwards Lifesciences$4.35 billion9.86$1.05 billion$1.8637.20
Boston Scientific$10.74 billion4.61$4.70 billion$1.5822.39

Boston Scientific has higher revenue and earnings than Edwards Lifesciences. Boston Scientific is trading at a lower price-to-earnings ratio than Edwards Lifesciences, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations for Edwards Lifesciences and Boston Scientific, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Edwards Lifesciences171502.61
Boston Scientific021933.04

Edwards Lifesciences currently has a consensus target price of $82.7727, suggesting a potential upside of 19.63%. Boston Scientific has a consensus target price of $44.6522, suggesting a potential upside of 26.21%. Given Boston Scientific's stronger consensus rating and higher probable upside, analysts clearly believe Boston Scientific is more favorable than Edwards Lifesciences.

Summary

Boston Scientific beats Edwards Lifesciences on 9 of the 15 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Abbott Laboratories logo
ABT
Abbott Laboratories
2.3$92.23+0.6%$163.14 billion$31.90 billion46.35Heavy News Reporting
Medtronic logo
MDT
Medtronic
2.7$93.16+0.9%$124.96 billion$28.91 billion26.24Analyst Report
Stryker logo
SYK
Stryker
2.3$183.94+0.1%$68.95 billion$14.88 billion32.33
Intuitive Surgical logo
ISRG
Intuitive Surgical
1.6$580.48+0.9%$67.69 billion$4.48 billion50.00
Becton Dickinson and logo
BDX
Becton Dickinson and
2.1$245.03+1.4%$66.45 billion$17.29 billion73.80Heavy News Reporting
Boston Scientific logo
BSX
Boston Scientific
2.3$35.38+0.3%$49.51 billion$10.74 billion11.64Heavy News Reporting
Baxter International logo
BAX
Baxter International
1.9$87.21+0.1%$44.23 billion$11.36 billion26.35
DexCom logo
DXCM
DexCom
1.5$407.35+1.8%$37.62 billion$1.48 billion256.19
IDEXX Laboratories logo
IDXX
IDEXX Laboratories
1.3$334.76+0.1%$28.43 billion$2.41 billion66.95Heavy News Reporting
ResMed logo
RMD
ResMed
1.2$192.48+0.8%$27.85 billion$2.61 billion54.53Insider Selling
Heavy News Reporting
Teleflex logo
TFX
Teleflex
1.7$368.15+0.2%$17.09 billion$2.60 billion31.49
Hologic logo
HOLX
Hologic
1.5$57.86+1.5%$14.94 billion$3.37 billion25.27Analyst Upgrade
Insider Selling
Steris logo
STE
Steris
2.0$154.01+0.2%$13.08 billion$3.03 billion32.29
Insulet logo
PODD
Insulet
1.4$201.11+3.2%$12.69 billion$738.20 million2,514.19
Masimo logo
MASI
Masimo
1.2$231.72+0.9%$12.54 billion$937.84 million62.80
ABIOMED logo
ABMD
ABIOMED
1.3$263.84+3.3%$11.88 billion$840.88 million59.69
Varian Medical Systems logo
VAR
Varian Medical Systems
1.6$122.39+0.7%$11.11 billion$3.23 billion45.00
Hill-Rom logo
HRC
Hill-Rom
1.8$111.57+1.0%$7.43 billion$2.91 billion51.18Insider Selling
Globus Medical logo
GMED
Globus Medical
1.8$49.16+1.0%$4.80 billion$785.37 million33.90
Integra Lifesciences logo
IART
Integra Lifesciences
1.7$48.72+0.1%$4.13 billion$1.52 billion157.16Heavy News Reporting
Wright Medical Group logo
WMGI
Wright Medical Group
1.3$29.70+0.2%$3.83 billion$920.90 million-40.13Insider Selling
NuVasive logo
NUVA
NuVasive
1.6$57.08+0.5%$2.93 billion$1.17 billion49.64
Integer logo
ITGR
Integer
1.9$72.28+0.9%$2.37 billion$1.26 billion22.66
CONMED logo
CNMD
CONMED
1.8$73.01+0.7%$2.08 billion$955.10 million76.85
AtriCure logo
ATRC
AtriCure
1.4$46.30+2.2%$1.86 billion$230.81 million-38.58Analyst Upgrade
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$32.22+2.9%$1.14 billion$248.02 million-103.93
Cryolife logo
CRY
Cryolife
1.6$19.62+3.0%$740.47 million$276.22 million-150.92Analyst Report
Orthofix Medical logo
OFIX
Orthofix Medical
1.4$32.19+0.5%$618.11 million$459.95 million-128.75Analyst Upgrade
SurModics logo
SRDX
SurModics
1.4$43.00+0.2%$585.05 million$100.08 million87.76
AngioDynamics logo
ANGO
AngioDynamics
2.0$10.33+2.1%$388.67 million$359.48 million8.01
Alphatec logo
ATEC
Alphatec
1.4$4.96+5.2%$317.68 million$113.43 million-4.35
Invacare logo
IVC
Invacare
1.4$6.45+0.3%$222.04 million$927.96 million-5.56
Accuray logo
ARAY
Accuray
1.5$2.17+1.8%$196.43 million$418.79 million108.55
Rockwell Medical logo
RMTI
Rockwell Medical
1.9$1.93+0.5%$133.31 million$61.30 million-3.64Analyst Upgrade
Cyberonics logo
CYBX
Cyberonics
0.6N/AN/A$0.00N/A0.00High Trading Volume
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.